Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients: https://t.co/PdVoRGm5C3

$CMRX #FDA #covid19 #coronavirus @chimerix #healthcare #stocks https://t.co/HBWsG2qJb5